P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

 

News Categories

 

 

 

Valchlor (Mechlorethamine) Antifungal Gel Launched in U.S.

First FDA-approved topical formulation of mechlorethamine (November 18)

Valchlor (Actelion Ltd.), the first FDA-approved topical formulation of mechlorethamine (commonly known as nitrogen mustard), is now available for patients in the U.S.

The gel, which is applied topically once a day, is an alkylating drug indicated to treat patients with stages IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) who have received prior skin-directed therapy.

Valchlor (mechlorethamine) gel 0.016% will be distributed in the U.S. by Accredo Specialty Pharmacy.

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma, a rare form of non-Hodgkin's lymphoma. In the U.S., approximately 20,000 patients are currently diagnosed with stage IA-IB MF-CTCL, qualifying it as a rare or orphan disease.

Source: Actelion Ltd.; November 18, 2013.

More stories